Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
QLatticeabzu.ai · Low evidenceAbzu applies AI to design and develop RNA therapies (siRNA, ASO, anti-miR) and operates a platform that programs RNA rather than discovers it. Their QLattice-based AI design platform can explore 100,000+ design variants, predict efficacy and developability, and shorten drug discovery cycles. They pursue targeted, extrahepatic delivery by using RNA as the delivery vehicle with programmable aptamers for cell-specific uptake, supported by partnerships (e.g., Contera Pharma) and ongoing fundraising.
Parse Score
Sources
en.wikipedia.org shapes more of what AI says about QLattice than any other source, at 100% of its citations.